Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

NCT03054532 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT03054532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03054532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
Lead sponsor
Singapore General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2017
Completion date
July 31, 2021
Enrollment
22 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma